Table III.
Prescription of coxibs and nsNSAIDs versus no NSAID in moderate and high CV risk patients versus low CV risk patients per UGI risk group.
| OR (95% CI) | Adj. OR (95% CI)2 | ||||||||
| UGI risk group | CV risk group | Number of patients | No NSAID n (%1) |
nsNSAID n (%1) |
Coxib n (%1) |
nsNSAID vs. no NSAID |
coxib vs. no NSAID |
nsNSAID vs. no NSAID |
coxib vs. no NSAID |
| Low | Low | 305 168 | 226 617 (74.3) | 75 915 (24.9) | 2 636 (0.9) | 1 (ref.) | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| Moderate | 22 003 | 15 842 (72.0) | 5 836 (26.5) | 325 (1.5) | 1.1 (1.1–1.1) | 1.7 (1.5–1.9) | 0.9 (0.9–0.9) | 1.1 (1.0–1.2) | |
| High | 8 385 | 6 246 (74.5) | 2 002 (23.9) | 137 (1.6) | 1.0 (0.9–1.0) | 1.9 (1.6–2.3) | 0.8 (0.8–0.8) | 1.3 (1.1–1.5) | |
| Moderate | Low | 34 692 | 24 776 (71.4) | 9 164 (26.4) | 752 (2.2) | 1 (ref.) | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| Moderate | 21 058 | 14 945 (71.0) | 5 708 (27.1) | 405 (1.9) | 1.0 (1.0–1.1) | 0.9 (0.8–1.0) | 1.0 (1.0–1.1) | 0.9 (0.8–1.2) | |
| High | 8 093 | 6 003 (74.2) | 1 920 (23.7) | 170 (2.1) | 0.9 (0.8–0.9) | 1.0 (0.8–1.1) | 0.8 (0.8–0.9) | 1.0 (0.8–1.2) | |
| High | Low | 25 674 | 19 365 (75.4) | 5 536 (21.6) | 773 (3.0) | 1 (ref.) | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| Moderate | 24 123 | 18 183 (75.4) | 5 308 (22.0) | 632 (2.6) | 1.0 (1.0–1.1) | 0.9 (0.8–1.0) | 1.0 (1.0–1.1) | 0.9 (0.8–1.0) | |
| High | 25 005 | 20 055 (80.2) | 4 324 (17.3) | 626 (2.5) | 0.8 (0.7–0.8) | 0.8 (0.7–0.9) | 0.8 (0.7–0.8) | 0.8 (0.7–0.9) | |
Notes: nsNSAID: non-selective non-steroidal anti-inflammatory drug; NSAID: non-steroidal anti-inflammatory drug; CV: cardiovascular; UGI: upper gastrointestinal. 1Row percentage. 2Adjusted for age, gender, prescription of NSAIDs in six months prior, type of MSK complaint, and presence of renal insufficiency.